{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007858","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.703644+00:00","generated_at":"2026-06-18T03:17:25.837556+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenon Pharmaceuticals adopts Executive Incentive Plan; sets 2023 salaries and 2022 bonuses for executives","bullets":["CEO Ian Mortimer: 2022 non-equity bonus $343,422; 2023 base salary $665,000.","CFO Sherry Aulin: 2022 bonus $178,619; 2023 base salary $465,000.","CMO Christopher Kenney: 2022 bonus $195,300; 2023 base salary $510,000.","CEO eligible for up to 60% base salary under new plan; CFO and CMO eligible for up to 40%.","Incentive Compensation Plan allows cash awards based on corporate goals (R&D, regulatory, financial milestones)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007858","json":"https://secwatch.observer/filing/0000950170-23-007858.json","markdown":"https://secwatch.observer/filing/0000950170-23-007858.md","text":"https://secwatch.observer/filing/0000950170-23-007858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/0000950170-23-007858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/xene-20230310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:17:25.837556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}